LEGN - Blood Cancer Player Arcellx's Lead Product Exceeds Expectations Analysts Say | Benzinga
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or refractory multiple myeloma.
The interim anito-cel Phase 1 clinical results (October 15, 2023 cutoff date) demonstrate deep and durable responses. Of the 38 evaluable patients with a median follow-up of 26.5 months:
- A 100% overall response rate (ORR) was achieved in all patients per IMWG criteria.
- 29/38 evaluable patients achieved a complete response (CR) or a stringent complete response (sCR) (>CR rate, 76%)
- 35/38 patients achieved a very good partial ...